论文部分内容阅读
结核放线菌素-N是继利福平用于临床以后的又一种新抗结核药,近几年来在日本使用较广。1968年永田等从灰色环生链霉菌变异株即结核放线菌B-386(Streptomyces griseoverticillatus var.tuberacticus B-386)培养滤液中提出的肽类抗菌物质,称结核放线菌素(Tuberactinomycin或TuberactinomycinA,简称TUM)。1971年安藤用结核放线菌B-386经亚硝基胍(N-methyl-N′-nitro-N-nitrosoguanidine)处理,获得与母株不同的变异菌株-结核放线菌N6-130,从该变异菌株培养滤液中提出的碱性肽类物质,称为结核放
Streptomycin-N is another new anti-tuberculosis drug following rifampicin for clinical use and has been widely used in Japan in recent years. In 1968 Nagata et al. Proposed peptide antibacterial substances from the culture filtrate of Streptomyces griseoverticillatus var. Tuberacticus B-386, which is called Tubractinomycin or Tuberactinomycin A, Referred to as TUM). In 1971, Ando was treated with N-methyl-N’-nitro-N-nitrosoguanidine by actinomycetes B-386 to get the actinomycetes N6-130, The mutant strain culture filtrate proposed alkaline peptides, known as tuberculosis release